Adeno-associated Viral (AAV) vectors and Lentiviral vectors (LVV) are the most common delivery vehicles for gene and cell therapies, respectively, currently.
We identified 319 adeno-associated viral and lentiviral vector therapeutic companies worldwide.
See table and graphics for more details.👇
Interesting findings:
- 219 AAV and lenti companies are based in the U.S.
- 100 AAV and lenti companies are based outside the U.S.
- 25 companies working on both AAV and lenti vectors
FIG 1: Key Differences Between AAV & Lenti Vectors
FIG 2: AAV & Lenti Vector Therapeutic Companies
***
Find companies that are developing therapeutics that utilize adeno-associated viral vectors and/or lentiviral vectors.
Get access to our AAV/LV company list https://www.biopharmiq.com/aav-lv-vector-report
---
Article History:
JD, DV, EV, DG (07/18/24)
This article is not investment or legal advice.
Comments